Compare OBAI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBAI | MBAI |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 85 |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.3M |
| IPO Year | N/A | N/A |
| Metric | OBAI | MBAI |
|---|---|---|
| Price | $1.03 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.1M | 63.0K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $1.29 |
| 52 Week High | $19.95 | $3.92 |
| Indicator | OBAI | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 68.91 | 41.42 |
| Support Level | $0.45 | $1.30 |
| Resistance Level | $1.66 | $1.83 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 54.15 | 20.00 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.